This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

SAC Upped Dendreon Exposure Before Blowup

Stocks in this article: DNDN AMGN BIIB GILD AMRN ACOR PFE

BOSTON ( TheStreet) -- More evidence emerged Monday suggesting billionaire hedge fund manager Steven Cohen lost a bundle when Dendreon (DNDN) blew up.

Cohen's SAC Capital Advisors increased its monstrous Dendreon position by 5% to 8.6 million shares, or $351 million, at the end of the June quarter, according to the fund's 13F filed with the Securities and Exchange Commission Monday night.

Dendreon was the largest single stock holding by position value in SAC's portfolio, according to the new 13F.

It's not known if Cohen sold any or all of his Dendreon position (or was hedged with a short position) before the company reported disastrous second-quarter results on Aug. 3 due to slower-than-expected sales of its Provenge prostate cancer therapy. But if Cohen held those 8.6 million shares of Dendreon, his fund would have lost more than $200 million.

Hedge funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F filed SEC within 45 days of the end of a quarter. Funds aren't required to report short positions betting on declines. SAC Capital Advisors ended the second quarter with 2,033 reported holdings with a market value of $17.4 billion.

In other biotech and drug holdings, SAC eliminated entirely or sold large stakes in Amgen (AMGN - Get Report), Biogen Idec (BIIB - Get Report), Allos Therapeutics (ALTH), Cubist Pharmaceuticals (CBST), Gilead Sciences (GILD - Get Report) and Inspire Pharmaceuticals (ISPH) during the second quarter, according to the fund's 13F.

SAC increased positions in Acorda Therapeutics (ACOR - Get Report), Human Genome Sciences (HGSI), Amarin (AMRN), InterMune (ITMN), Pfizer (PFE - Get Report), and Amylin Pharmaceuticals (AMLN).

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,493.46 -185.24 -1.05%
S&P 500 2,037.77 -19.32 -0.94%
NASDAQ 4,709.6940 -62.0690 -1.30%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs